CD27 and nonpapillary renal cell carcinoma: Following the encouraging results of different studies supporting the role of B cells within tertiary lymphoid structures (TLS) in fostering antitumor responses across different solid tumors treated with ICI, fresh blood immune-monitoring of advanced ccRCC patients receiving nivolumab within the NIVOREN study revealed that pre-existing high levels of unswitched memory B cells (CD19+CD27+IgD+IgM+) were associated with improved clinical outcomes (n = 44) [overall survival (OS) HR = 0.08, P = 0.002 and progression-free survival (PFS) HR = 0.54, P = 0.048] [28] (Table 1).